Steve Hanke - Amgen Independent Chairman of the Supervisory Board
| AMG Stock | EUR 290.90 4.35 1.47% |
Chairman
Prof. Steve H. Hanke is Chairman of the Supervisory Board of AMG Advanced Metallurgical Group NV since 2013. He is a Professor of Applied Economics and CoDirector of the Institute for Applied Economics, Global Health and the Study of Business Enterprise at the Johns Hopkins University in Baltimore since 2019.
| Age | 77 |
| Tenure | 6 years |
Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| David Kaplan | Ares Management Corp | 56 | |
| Bennett Rosenthal | Ares Management Corp | 60 | |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jackson Dunckel, Member of the Management Board, Chief Financial Officer | ||
| Michele Fischer, Vice President IR Contact Officer | ||
| Heinz Schimmelbusch, Chairman of the Management Board, Chief Executive Officer | ||
| Dagmar Bottenbruch, Independent Member of the Supervisory Board | ||
| Eric Jackson, Member of the Management Board and Presidentident of the AMG Processing Division, COO | ||
| Donatella Ceccarelli, Independent Member of the Supervisory Board | ||
| Willem Hassel, Independent Vice Chairman of the Supervisory Board | ||
| Frank Lohner, Independent Member of the Supervisory Board | ||
| Herbert Depp, Independent Member of the Supervisory Board | ||
| Steve Hanke, Independent Chairman of the Supervisory Board |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 163.09 B | |||
| Price To Book | 39.61 X | |||
| Price To Sales | 5.64 X | |||
| Revenue | 26.32 B | |||
| EBITDA | 12.17 B | |||
| Net Income | 6.55 B | |||
| Total Debt | 37.35 B | |||
| Cash Flow From Operations | 9.72 B | |||
| Price To Earnings To Growth | 1.55 X | |||
| Number Of Employees | 20 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Amgen Stock Analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.